Ardelyx to Present at the 2015 Leerink Global Healthcare Conference
FREMONT, Calif., Feb. 9, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab, President and Chief Executive Officer and David Rosenbaum Ph.D., Senior Vice President, Drug Development, will present a company overview at the 2015 Leerink Global Healthcare Conference at 8:05 a.m. EST on February 12, 2015 at the Waldorf Astoria in New York City.
The analyst-led fireside chat will be available through a live audio webcast accessible through a link in the Investor Relations section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available for 90 days at the site after the presentation.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor.
Ardelyx formed a collaborative partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. In addition to tenapanor, the Company has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in CKD-5D, a program licensed to Sanofi, and independently is advancing several additional research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
SOURCE Ardelyx, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article